Literature DB >> 16250251

Metabolism and excretion of the antiepileptic/antimigraine drug, Topiramate in animals and humans.

G W Caldwell1, W N Wu, J A Masucci, L A McKown, D Gauthier, W J Jones, G C Leo, B E Maryanoff.   

Abstract

The metabolism and excretion of 2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate (TOPAMAX, topiramate, TPM) have been investigated in animals and humans. Radiolabeled [14C] TPM was orally administered to mice, rats, rabbits, dogs and humans. Plasma, urine and fecal samples were collected and analyzed. TPM and a total of 12 metabolites were isolated and identified in these samples. Metabolites were formed by hydroxylation at the 7- or 8-methyl of an isopropylidene of TPM followed by rearrangement, hydroxylation at the 10-methyl of the other isopropylidene, hydrolysis at the 2,3-O-isopropylidene, hydrolysis at the 4,5-O-isopropylidene, cleavage at the sulfamate group, glucuronide conjugation and sulfate conjugation. A large percentage of unchanged TPM was recovered in animal and human urine. The most dominant metabolite of TPM in mice, male rats, rabbits and dogs appeared to be formed by the hydrolysis of the 2,3-O-isopropylidene group.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16250251     DOI: 10.1007/BF03190614

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  11 in total

Review 1.  Current and investigational antiobesity agents and obesity therapeutic treatment targets.

Authors:  Harold E Bays
Journal:  Obes Res       Date:  2004-08

Review 2.  Uses of topiramate in the treatment of alcohol dependence.

Authors:  Bankole A Johnson
Journal:  Expert Rev Neurother       Date:  2004-09       Impact factor: 4.618

Review 3.  An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action.

Authors:  R P Shank; J F Gardocki; A J Streeter; B E Maryanoff
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

4.  Pharmacokinetics and metabolism of topiramate.

Authors:  B F Bourgeois
Journal:  Drugs Today (Barc)       Date:  1999-01       Impact factor: 2.245

5.  Topiramate: preclinical evaluation of structurally novel anticonvulsant.

Authors:  R P Shank; J F Gardocki; J L Vaught; C B Davis; J J Schupsky; R B Raffa; S J Dodgson; S O Nortey; B E Maryanoff
Journal:  Epilepsia       Date:  1994 Mar-Apr       Impact factor: 5.864

6.  A pilot trial of topiramate for the treatment of cocaine dependence.

Authors:  Kyle M Kampman; Helen Pettinati; Kevin G Lynch; Charles Dackis; Thorne Sparkman; Catherine Weigley; Charles P O'Brien
Journal:  Drug Alcohol Depend       Date:  2004-09-06       Impact factor: 4.492

7.  Pharmacokinetics and bioavailability of topiramate in the beagle dog.

Authors:  A J Streeter; P L Stahle; M L Holland; J F Pritchard; A R Takacs
Journal:  Drug Metab Dispos       Date:  1995-01       Impact factor: 3.922

8.  Topiramate in migraine prevention.

Authors:  Stephen D Silberstein
Journal:  Expert Rev Neurother       Date:  2003-11       Impact factor: 4.618

Review 9.  Topiramate: as monotherapy in newly diagnosed epilepsy.

Authors:  John Waugh; Karen L Goa
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds.

Authors:  B E Maryanoff; S O Nortey; J F Gardocki; R P Shank; S P Dodgson
Journal:  J Med Chem       Date:  1987-05       Impact factor: 7.446

View more
  4 in total

1.  International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe.

Authors:  Sofie F M Bhatti; Luisa De Risio; Karen Muñana; Jacques Penderis; Veronika M Stein; Andrea Tipold; Mette Berendt; Robyn G Farquhar; Andrea Fischer; Sam Long; Wolfgang Löscher; Paul J J Mandigers; Kaspar Matiasek; Akos Pakozdy; Edward E Patterson; Simon Platt; Michael Podell; Heidrun Potschka; Clare Rusbridge; Holger A Volk
Journal:  BMC Vet Res       Date:  2015-08-28       Impact factor: 2.741

2.  Intravenous Topiramate: Pharmacokinetics in Dogs with Naturally Occurring Epilepsy.

Authors:  Irene Vuu; Lisa D Coles; Patricia Maglalang; Ilo E Leppik; Greg Worrell; Daniel Crepeau; Usha Mishra; James C Cloyd; Edward E Patterson
Journal:  Front Vet Sci       Date:  2016-12-05

3.  Preparation and evaluation of bilayer-core osmotic pump tablets contained topiramate.

Authors:  Wen Lin; Yinke Li; Qiongzhi Shi; Xiangru Liao; Yuan Zeng; Wei Tian; Xiangyang Xie; Hui Liu
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

4.  Effect of experimentally induced hepatic and renal failure on the pharmacokinetics of topiramate in rats.

Authors:  Kamal M Matar; Yasin I Tayem
Journal:  Biomed Res Int       Date:  2014-06-09       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.